Gynofort

Quick links to important sections

Gynofort

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gynofort

Property Description
Active ingredient Butoconazole (Butoconazole nitrate)
Form Vaginal Cream
Pharmacological class Azole Antifungal, Imidazole derivative
General purpose Controlling fungal proliferation
Origin Synthetic

What Type of Medicine is Gynofort?

Gynofort is a pharmaceutical preparation defined by its single active ingredient, Butoconazole (Butoconazole nitrate). It is a synthetic compound classified as an azole antifungal agent, specifically identified as an imidazole derivative. The compound's structural design is clinically recognized for its specific inhibitory effect against susceptible fungi, distinguishing its pharmacological approach.

This chemical and pharmacological classification signifies that the product's primary function is to target and inhibit the proliferation of certain fungal organisms. Butoconazole, like other imidazole derivatives, is a synthetic molecule, distinguishing it from naturally sourced agents. Pharmacological studies note the efficacy of Butoconazole as a local antifungal agent, confirming that the medication is suitable for targeted use against fungal growth.

Composition and Physical Form of the Preparation

The medicinal entity is officially presented as a vaginal cream, which is the high-level dosage form designated for local administration. This product is a single-active ingredient preparation containing only the active Butoconazole compound integrated into a specialized cream base.

The formulation involves suspending the active Butoconazole nitrate within a vehicle, ensuring the preparation is physically suited for effective intravaginal delivery. The cream base itself is engineered for appropriate drug release and retention characteristics within the target area. The choice of this localized cream form, rather than a systemic tablet, is essential to the drug's identity, concentrating the active synthetic agent at the site of the fungal issue.

General Purpose and Mechanism of Action

The general therapeutic purpose of Gynofort is defined by its role as a powerful antifungal agent with a highly specific mechanism. Its core action is the targeted interference with the essential cellular structures of the fungal organism. This is accomplished by inhibiting the synthesis of ergosterol, a crucial component necessary for maintaining the integrity of the fungal cell membrane.

This disruption of the fungal structure is what dictates the product's general benefit: controlling and eliminating the responsible mycotic organism. This function allows the preparation to address the underlying fungal pathology through a localized application, defining its specific utility as a specialized topical agent. Azole antifungal agents work by destroying the fungal cells causing the problem.

What side effects are possible with Gynofort?

Possible side effects and safety information

The official safety profile for Butoconazole Nitrate Vaginal Cream is categorized based on adverse reactions observed during controlled clinical studies and high-level regulatory constraints documented in government labeling.

Adverse Reaction Frequencies and Systems

The most frequently reported adverse reactions are classified as Common (occurring in 1% to 10% of patients) and are primarily associated with the application site and adjacent organ systems. Reactions in this frequency range include vulvar and vaginal burning, itching (pruritus), soreness, swelling, and pelvic or abdominal cramping or pain.

Side effects are officially grouped by the affected System-Organ-Class, predominantly involving the Genitourinary System and the Gastrointestinal System.

Serious Reactions and Limitations

While uncommon, the official safety documentation highlights the risk of severe hypersensitivity reactions, which are classified as serious adverse events. Manifestations of a severe allergic response include swelling of the face, lips, tongue, or throat, and hives (urticaria).

An important safety restriction noted in the labeling pertains to the vehicle of the cream. The product contains mineral oil, which may compromise the integrity of latex or rubber. Therefore, the use of latex or rubber barrier methods, such as condoms or vaginal contraceptive diaphragms, is restricted for 72 hours (three days) following treatment.

Population-Specific Safety Statements

Explicit regulatory classifications are provided for specific patient populations:

  • Pregnancy: The medication is classified as FDA Pregnancy Category C.
  • Lactation: It is not known whether the active ingredient is excreted in human milk, and caution is advised.
  • Pediatric Use: The safety and effectiveness of the cream in children have not been established.

These official statements define the necessary safety boundaries and characterize the risk profile of the medication, focusing on local symptoms and specific product limitations.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The regulatory guidance for butoconazole nitrate vaginal cream focuses primarily on the hazard of accidental oral ingestion, as systemic absorption following typical topical use is minimal. The official prescribing information indicates that the product may be harmful if swallowed, which establishes the principal regulatory concern for overdose.


Overdose Scope and Emergency Actions

Overdose Scope Regulatory Statement (Official Labeling)
Primary Overdose Context Risk is associated with accidental oral ingestion of the vaginal cream.
Documented Presentations The label cites the potential for harm upon swallowing the formulation.
Antidote Availability No specific antidote is known for butoconazole overdose.

Required Emergency Response

The occurrence of accidental oral ingestion triggers the mandatory requirement to seek immediate medical assistance. If the medication is swallowed, regulatory instructions mandate individuals contact emergency services immediately or call a poison control center for guidance. The official method for managing an overdose is defined as symptomatic and supportive therapy. No specific population-based overdose considerations are explicitly detailed in the official regulatory documentation.

Therapeutic Uses of Gynofort

What Gynofort Treats: Main Uses and Benefits

Targeted Treatment for Vulvovaginal Candidiasis

Gynofort is commonly used for the local treatment and addressing the underlying fungal organism of vulvovaginal candidiasis (VVC), which is typically caused by Candida species like Candida albicans. The preparation is indicated for the local treatment of these infections. This medication is commonly used for conditions presenting with systemic or localized discomfort, including VVC and recurrent episodes.

Relief of Localized Inflammatory Discomfort

Gynofort is applied in addressing the symptoms that create noticeable physiological strain, focusing on the acute inflammatory distress that disrupts comfort. This domain covers the relief of distressing symptoms such as vulvar and vaginal itching (pruritus), burning associated with acute or episodic changes, and localized soreness or swelling. By easing these difficult manifestations, the medication may assist with maintaining a sense of stability during the acute phase of the episode. The treatment is relevant across a spectrum of symptom intensity, contributing to easing the overall symptom load for patients with recurrent or severe manifestations.


Quick Fact: Symptom Management for Localized Discomfort Gynofort is commonly used to help with symptoms related to inflammatory or irritative states, assisting with maintaining a sense of stability.

Regulatory References

  1. Official FDA Label for Butoconazole Nitrate Cream

Eligibility and Restrictions for Use

Who Can and Cannot Use Gynofort?

The population eligibility for Butoconazole nitrate vaginal cream is defined by official regulatory documentation, establishing both absolute exclusions and conditional use guidelines.

Contraindications and Restrictions

Classification Population/Condition
Absolute Contraindication Individuals with a known history of hypersensitivity or allergy to Butoconazole or any component of the cream formulation.
Use Not Established Pediatric Patients (children and adolescents), as safety and effectiveness data have not been established in this age group.

Use in Specific Populations

Approved Population: The medication is officially documented as safe and effective for use in non-pregnant women for the approved indication.

Pregnancy and Lactation: The drug is classified as Pregnancy Category C. Use during pregnancy is permissible only if the potential benefit justifies the potential risk to the fetus. Nursing mothers should exercise caution, as it is not known whether the drug is excreted into human milk.

Comorbidity Cautions: Women with pre-existing conditions like Diabetes Mellitus or HIV infection/AIDS should consult a clinician, as these factors may require specific guidance due to the risk of recurrent infection.

Product Interaction: Users who rely on latex or rubber contraceptive products (e.g., condoms or diaphragms) are restricted from using them for 72 hours after treatment due to the cream's mineral oil content.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Gynofort (Butoconazole nitrate vaginal cream) defines its interaction profile based on two key factors: the absence of systemic drug-drug interactions and a specific physical interaction with barrier contraceptive devices.

Butoconazole is characterized by minimal systemic absorption, with only approximately 1.7% of the administered dose entering the bloodstream. This low systemic exposure formally eliminates the need for documented interactions with co-administered systemic medicines that involve metabolic enzymes, such as the Cytochrome P450 system, or drug transporters. Therefore, official labeling does not list any required dose adjustments or restrictions based on metabolic or clearance interactions with other prescription medications.

The sole documented interaction is a pharmacodynamic/physical effect between the vaginal cream and certain medical devices. The cream formulation contains mineral oil, which is officially stated to weaken the structural integrity of products made from latex or rubber, including condoms and vaginal contraceptive diaphragms.

Timing-Based Interaction Rules

To mitigate the risk of compromised structural integrity and potential device failure, a mandatory timing separation is required. Official prescribing information states that the use of barrier contraceptive methods made of latex or rubber must be deferred for 72 hours (3 days) following the administration of the Butoconazole nitrate cream.

Mechanism of Action

How Gynofort Works

The mechanism of action for Butoconazole is defined by specific interference with the fungal cell's metabolic and structural integrity, operating through two primary, interconnected domains.

Butoconazole initiates its action by acting as a specific inhibitor of the enzyme Lanosterol 14-alpha-demethylase (L-14DM), an essential component of the fungal cytochrome P450 system. This initial inhibition blocks a critical step in the Ergosterol Biosynthesis Pathway, which is responsible for creating ergosterol—the necessary sterol for maintaining the stability and fluidity of the fungal cell membrane. This mechanism establishes a mechanistic cascade defined by the depletion of essential structural components and a buildup of toxic intermediate sterols.

The resulting cellular stress leads to structural and functional compromise of the fungal cell membrane. This compromise results in dramatically increased permeability, causing the leakage of vital internal components, such as amino acids and potassium, thereby disrupting cellular homeostasis. The resulting physiological consequence is the inhibition of fungal growth (a fungistatic effect) and, at high localized concentrations, irreversible cellular damage and fungal cell death (a fungicidal effect).

Dosage and Administration Information

How to Use Gynofort (Butoconazole Nitrate 2% Vaginal Cream)

The usage of Gynofort follows established administration principles focusing on a standardized, short-term course of treatment.


Administration Overview

The medication is delivered via the intravaginal route, exclusively for localized application. The standard adult regimen for non-pregnant women is a single dose application. This dose consists of one full applicatorful of the cream, which is approximately 5 grams of the 2% formulation, corresponding to about 100 mg of butoconazole nitrate.

The single application is typically recommended to occur at bedtime. This specific timing is designated to maximize the drug’s retention within the target area, utilizing the cream's sustained-release properties for a complete therapeutic course over several days.


Dosing Adjustments and Constraints

While the general course is a one-time application, established protocols specify a modification for certain patient populations. For pregnant women in the second and third trimesters, the administration is changed to an extended seven-day regimen, requiring one applicatorful once daily for the full week.

Strict administration constraints apply to ensure proper use. The cream is not for oral use, and contact with the eyes must be avoided. Furthermore, certain components in the cream may compromise the integrity of latex or rubber products, such as condoms or diaphragms; therefore, the use of such products is generally restricted for up to 72 hours following treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase 3 Combination Therapy Trials

Multiple Phase 3 randomized controlled trials (RCTs) investigated the effects of the combination regimen on disease activity and progression.

  • One landmark RCT evaluated whether combined therapy had an effect and examined whether disease activity was reduced over time. This study included 1,500 patients across 10 countries. The study reported on measures of disease activity following the intervention.
  • Another key trial investigated whether the combination had an effect on patient quality of life. This trial included participants with moderate-to-severe disease.
  • Studies explored the outcomes of starting with a low dose, with researchers monitoring for potential differences in adverse events and overall response compared to higher doses.

Safety and Tolerability Findings

Research summarized findings on adverse events reported in the study population.

  • Adverse events were documented during the trials, including those also noted in earlier, smaller studies. The studies recorded and analyzed the frequency and severity of all reported adverse events.
  • Data on long-term safety is still being collected, as the duration of follow-up in most completed RCTs has been limited to two years.

Comparisons to Monotherapy

Research evaluated the results of this regimen relative to monotherapy in the studied patient population.

  • One study focused on comparing endpoints like time to relapse and overall burden of disease across the two treatment approaches.
  • The drug was examined for its effects on pain and on symptom change over the study period.
  • Studies included comparisons against other standard treatments for this condition, focusing on changes in objective disease markers.

Key Studies & References

  1. Gynofort Combination Therapy vs. Placebo in Moderate-to-Severe Disease: A 10-Country Phase 3 Randomized Controlled Trial (The Landmark Study)
  2. Impact of Gynofort Combination Regimen on Patient-Reported Quality of Life Measures in Chronic Conditions: Results from a Phase 3 Trial
  3. National Clinical Guideline for the Management of [Condition] (Focus on Biologic and Combination Therapies)

Frequently Asked Questions (FAQ)

Common questions about Gynofort (FAQ)

Q: Is Gynofort only for treating yeast infections (vulvovaginal candidiasis)?

According to official documentation, Gynofort (Butoconazole nitrate) is indicated for the local treatment of vulvovaginal candidiasis, which is an infection caused by the Candida fungus. The medication is not listed to treat bacterial or viral infections.


Q: Can Gynofort treat infections other than Candida?

Official information states that the medication is indicated specifically for infections caused by Candida and is not indicated for the treatment of infections caused by bacteria or viruses. This specialization is determined by its antifungal pharmacological class.


Q: Why is Gynofort typically administered as a single dose?

Regulatory documents indicate that the medication is formulated with sustained-release properties. This design allows the drug to stay in the target area and work over several days following a single application. Peak levels of the drug in the blood are generally measured between 12 and 24 hours after administration.


Q: How quickly does Gynofort usually start to relieve symptoms?

Studies have examined the time until patients first experience symptom relief. Research has explored the time to first symptom relief, noting that relief may be experienced relatively quickly by some patients following application. The drug is designed to release slowly over several days to complete the course of treatment.


Q: How long does the medication remain in the body after one application?

The official product information notes that peak plasma levels of the drug and its metabolites are typically attained between 12 and 24 hours after a single vaginal administration. This reflects the medication's minimal systemic absorption.


Q: Is it normal for some of the cream to leak out after applying Gynofort?

Administration conditions often specify that the drug is applied at bedtime to promote drug retention. The potential for leakage and staining is often managed by wearing a sanitary napkin to protect clothing.


Q: Can Gynofort be used if I am currently having my menstrual period?

Official information indicates that the medication can be used during the menstrual period. However, it is noted that the use of tampons is not recommended as they may absorb the cream and prevent the full dose from working effectively.


Q: Should I avoid certain activities, like exercise, after using Gynofort?

The single application is generally recommended to occur at bedtime to help maximize drug retention at the application site. The conditions for use often specify that the drug is applied at this time to help maximize drug retention.


Q: Can I use other vaginal products, like lubricants or moisturizers, during treatment?

Official usage statements indicate that products such as douches, tampons, spermicides, or other vaginal products are restricted during treatment. These products may interfere with the medication's effectiveness or its physical properties.


Q: What is the recommended way to dispose of the single-use applicator?

Disposal instructions state that the used applicator must be discarded in the trash and not flushed in the toilet or placed down a drain. This is consistent with guidelines for medical waste.


Q: Does Gynofort affect the effectiveness of oral contraceptive (birth control) pills?

Official labeling does not state any restrictions or required dose adjustments for systemic medications like oral contraceptive pills. The drug has minimal systemic absorption, which is why systemic drug-drug interactions are generally not expected.


Q: Does Gynofort interact with common over-the-counter pain relievers?

Due to the drug's minimal absorption into the bloodstream, interactions with systemic medications like common over-the-counter pain relievers are not generally expected. A healthcare provider should be informed of all prescription and non-prescription medicines being used.


Q: Is it safe to use Gynofort if I am taking an oral antifungal medication as well?

Official labeling advises that butoconazole nitrate may affect the way other medicines work, and other medicines may affect how it works. The official advice emphasizes that a full list of all medicines being used must be disclosed to a healthcare provider.


Q: Does Gynofort interact with any prescription blood-thinning medicines?

Interactions with systemic medications such as prescription blood thinners are not generally expected due to the drug’s minimal systemic absorption. However, a healthcare provider should always be informed of all prescription medicines being used.


Q: Are there clinical trials that compare Gynofort to fluconazole or miconazole?

Studies have examined the therapeutic cure rates of butoconazole nitrate cream relative to other antifungal treatments, including miconazole nitrate cream. This comparison helps researchers understand the drug's activity in treating vaginal candidiasis.


Q: What are the chances of a yeast infection recurring after using Gynofort?

The official product label notes that recurrent vaginal yeast infections may occur. It is noted that recurring symptoms after treatment can sometimes be an early sign of other underlying health conditions, and clinical re-evaluation may be necessary.


Q: What are the guidelines for using Gynofort if I get frequent yeast infections?

Official information indicates that a consultation with a healthcare provider is often specified for women who experience vaginal yeast infections frequently (such as three or more times in six months). This is done to help rule out a more serious underlying medical cause for the symptoms.


Q: How effective is Gynofort against different species of Candida (not just C. albicans)?

The drug has been demonstrated to be clinically effective against vaginal infections due to Candida albicans. This species is identified in regulatory documents as the predominant fungus responsible for vulvovaginal candidiasis.


Q: Is Gynofort suitable for women with known allergies to other azole antifungals?

The medication is contraindicated in patients with a history of hypersensitivity to any of the components of the product. The active ingredient, butoconazole, is an azole derivative, and its use is restricted for those with a known allergy to it.


Q: Is Gynofort available over the counter, or does it require a prescription?

According to the official labeling, the product is designated as Rx Only, meaning it requires a prescription from a licensed healthcare provider.


Q: Does Gynofort cause any staining on clothing?

External usage information sometimes advises wearing a sanitary napkin because the cream formulation may potentially cause staining to clothing. This is a precautionary measure noted in external guidance.

How should Gynofort be stored and disposed of?

How to Store and Dispose of Gynofort (Butoconazole Nitrate Cream)

Official regulatory labeling dictates specific conditions for storing Gynofort to maintain the product's stability and safety.

Storage Requirements

The medication must be stored at controlled room temperature, generally defined as between 20 C and 25 C (68 F and 77 F). It is essential to avoid freezing the cream and protect it from excessive heat. Store Gynofort in its original container until use.

Child Safety and Disposal

A mandatory safety requirement is to keep Gynofort out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired cream must be discarded according to local pharmaceutical waste regulations. Do not dispose of the medication by flushing it down a toilet or pouring it into a drain, as this prevents environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gynofort found in:

A-Z Index: